Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal

Dr. Betrand Tombal discusses the ongoing PEACE III trial evaluating enzalutamide alone versus enzalutamide plus radium-223 post the ERA-223 data. The interim safety analysis was presented at ASCO and the data demonstrated that there was an increase fracture rate with the addition of radium-223 to enzalutamide prior to mandating use of bone protecting agents. Pathological and non-pathological fract...

Contemporary Sequencing in the Treatment of Prostate Cancer - Neal Shore, Alicia Morgans and Charles Ryan

Alicia Morgans, Charles Ryan, and Neal Shore discuss the clinical evidence and considerations in treating prostate cancer progression as patients fail first-line treatment in the nmCRPC and advance to metastatic castration-resistant prostate cancer (mCRPC). They highlight the need to change the mechanism of action and the opportunities that each Sipuleucel-T, (Provenge®) an autologous cellular imm...

The Changing Therapeutic Landscape of Prostate Cancer- Nicholas Vogelzang

Dr. Nick Vogelzang discusses a brief history of the advancements in treating prostate cancer. He provides background on how we have arrived at where we are now with the advances in both the diagnosis and treatment of prostate cancer while talking with Alicia Morgans. Dr. Vogelzang reflects upon the time when we were relegated to using primitive bone scans to define disease to the current era of ad...

Improved Survival Outcomes of African America Men with mCRPC Treated with Sipuleucel-T - Kelvin Moses

Kelvin Moses explores the clinical benefit of sipuleucel-T treatment in African American men with advanced prostate cancer in this conversation with Alicia Morgans. A large volume of evidence has demonstrated that African American men have an increased risk of developing mCRPC and have higher mortality as compared with Caucasian men. Sipuleucel-T has demonstrated a survival benefit in men with met...

Treatment Decisions for Patients with Metastatic Castration-resistant Prostate Cancer: A Retrospective Study of Real-World Experience - Tia Higano

Alicia Morgans invites Tia Higano to discuss data analysis amongst patients with mCRPC who were enrolled in the Flatiron Health prostate cancer registry from 2013-2017. Findings include the discovery that 77% of patients receive some form of life-prolonging therapy and that only 60% of the patients ever received either denosumab or zoledronic acid. Alicia and Tia conclude by stating the importance...

The Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade - Wassim Abida

Wassim Abida joins Charles Ryan in a discussion on a JAMA Oncology published paper on the Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. Wassim details the prevalence of MSI-H/dMMR prostate cancer and the clinical benefit of anti–PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy in this molecularly defined population. The...

Introducing TIN 117m for Convention Electron Therapy of mCRPC - Suresh Srivastava

Suresh C. Srivastava presents the unique opportunities and future for nuclear medicine, including theragnostic radiopharmaceuticals for molecular imaging plus therapy and getting closer to personalized medicine, selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and eval...

Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad

(Length of Conversation: 13 min) Charles Ryan and Fred Saad discuss the data results in patients with mCRPC from a combined therapeutic approach with abiraterone and apalutamide. They discuss the rationale and theory behind these results. Later they move to discuss the quality of life analysis for patients with CRPC. A review of the SPARTAN trial and the optimistic results from his work. Biographi...

Prospective Study of Low-Dose Abiraterone with Food Versus Standard Dose Abiraterone in mCRPC - Russell Szmulewitz

(Length of Discussion: 21 min) Russell Szmulewitz talks with Alicia Morgans about a trial that evaluated abiraterone with food and how that might affect relative patient outcomes, such as PSA. This study sought to test the hypothesis that low-dose Abiraterone acetate (AA) (LOW; 250 mg with a low-fat meal) would have comparable activity to standard dosed AA (STD; 1,000 mg fasting) in patients with...

Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad

(Length of Conversation: 9 min) Fred Saad and Charles Ryan discuss the Movember Foundation sponsored, INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer Study (INTERVAL). This is a randomized phase 3 study of exercise in men with metastatic castrate-resistant prostate cancer (mCRPC). The objective of the study is to determine if high intensity aerobic and re...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.